Sonrotoclax
Modify Date: 2024-01-07 06:20:17
Sonrotoclax structure
|
Common Name | Sonrotoclax | ||
|---|---|---|---|---|
| CAS Number | 2383086-06-2 | Molecular Weight | 890.10 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C49H59N7O7S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SonrotoclaxSonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1]. |
| Name | Sonrotoclax |
|---|
| Description | Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; 每日一次, 持续 42 天; 患有急性淋巴细胞白血病 (ALL) 异种移植物的雌性 NCG 小鼠) 具有抗肿瘤活性并抑制肿瘤生长[1]。 Animal Model: Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts[1] Dosage: 5, 15, 50 mg/kg Administration: oral administration; daily, for 42 days Result: Inhibited tumor growth in a dose-dependent manner. |
| References |
[1]. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1. |
| Molecular Formula | C49H59N7O7S |
|---|---|
| Molecular Weight | 890.10 |